CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Venus Viva MDdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04827680
NCT04827680N/ACompleted
CompareCT.gov

Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring

Venus Concept·interventional·Posted Apr 1, 2021·Updated Oct 4, 2023

In Brief

A clinical study evaluating Venus Viva MD for Acne Scars - Mixed Atrophic and Hypertrophic. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 20 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Scars - Mixed Atrophic and Hypertrophic
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartMay 1, 2021
Primary CompletionJun 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago

Interventions

Venus Viva MDdevice

The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.